Clinical Study of PET/CT and Association With Metabolic Syndrome/Depressive Symptoms in Psoriasis

• Conditions: Psoriasis; Depression; Metabolic Syndrome

• Registration Number: NCT01661127
• Lead Sponsor: Pusan National University Hospital

Brief Summary

Psoriasis is associated with increases in markers of inflammation in the skin and blood and increasingly is thought to be a systemic inflammatory disease and risk factor for incident diabetes mellitus, myocardial infarction, stroke, and premature cardiovascular death. Furthermore, it is important for clinicians to be aware that psoriasis can have a substantial emotional impact on an individual, which is not necessarily related to the extent of skin disease.

FDG-PET/CT represents an innovative approach to studying systemic inflammation in a manner that is sensitive, quantifiable, and anatomically localizable. Also, recent study show that chronic disease such as end stage renal disease with depressive symptoms have decreased cerebral glucose metabolism in several brain areas in F-18-FDG PET/CT. So this protocol was designed to evaluate usefulness of PET/CT to detect systemic inflammation and abnormality of cerebral glucose metabolism and association with metabolic syndrome/major depressive symptoms in patients with psoriasis.

Detailed Description

10 Patients with psoriasis

1. Evaluate PASI score

2. Evaluate comorbidity with metabolic syndrome

* Body mass index(BMI)

* Checking blood pressure

* Checking blood sugar

* Smoking and drinking history

* Checking blood cholesterol level

* Risk factors of cardiovascular disease

3. PET/CT for measuring the extent and site of psoriasis with inflammation

Study Timeline

• Study Start: 2012-06
• Study First Submitted: 2012-08-07
• Study First Submitted QC: 2012-08-07
• Study First Posted: 2012-08-09
• Status Verified: 2014-11
• Last Update Submitted: 2014-11-03
• Last Update Posted: 2014-11-04
• Primary Completion: 2015-06
• Study Completion: 2015-12

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 10

Inclusion Criteria

• Histological diagnosis of plaque type psoriasis
• at least 18 years old

Read More

Exclusion Criteria

• those who cannot understand questionnaire
• those who take antidepressant

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Beck depression inventory scoring and Korean Hamilton depression scale scoring	Day 0 and 28 weeks later

Secondary Outcome Measures

Name	Time	Method
Brain glucose uptake using PET/CT	Day 0 and 28 weeks later

Trial Locations

Locations (1)

Department of dermatology, Pusan National University Hospital; 🇰🇷 Busan, Korea, Republic of